These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 19059064)

  • 1. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.
    Reynolds KK; Ramey-Hartung B; Jortani SA
    Clin Lab Med; 2008 Dec; 28(4):581-98. PubMed ID: 19059064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
    Ruano G; Kost JA
    Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics in pain management: the clinical need.
    Webster LR
    Clin Lab Med; 2008 Dec; 28(4):569-79. PubMed ID: 19059063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events in analgesic treatment with tramadol associated with CYP2D6 extensive-metaboliser and OPRM1 high-expression variants.
    Kim E; Choi CB; Kang C; Bae SC;
    Ann Rheum Dis; 2010 Oct; 69(10):1889-90. PubMed ID: 20444752
    [No Abstract]   [Full Text] [Related]  

  • 5. The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes.
    Zwisler ST; Enggaard TP; Noehr-Jensen L; Mikkelsen S; Verstuyft C; Becquemont L; Sindrup SH; Brosen K
    Fundam Clin Pharmacol; 2010 Aug; 24(4):517-24. PubMed ID: 19845769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genetic polymorphisms and human sensitivity to pain and opioids].
    Nishizawa D; Nagashima M; Satoh Y; Tagami M; Ikeda K
    Masui; 2009 Sep; 58(9):1093-101. PubMed ID: 19764431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complicated pain management in a CYP450 2D6 poor metabolizer.
    Foster A; Mobley E; Wang Z
    Pain Pract; 2007 Dec; 7(4):352-6. PubMed ID: 17986163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2D6 in the metabolism of opioids for mild to moderate pain.
    Leppert W
    Pharmacology; 2011; 87(5-6):274-85. PubMed ID: 21494059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
    Crews KR; Monte AA; Huddart R; Caudle KE; Kharasch ED; Gaedigk A; Dunnenberger HM; Leeder JS; Callaghan JT; Samer CF; Klein TE; Haidar CE; Van Driest SL; Ruano G; Sangkuhl K; Cavallari LH; Müller DJ; Prows CA; Nagy M; Somogyi AA; Skaar TC
    Clin Pharmacol Ther; 2021 Oct; 110(4):888-896. PubMed ID: 33387367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are mu-opioid receptor polymorphisms important for clinical opioid therapy?
    Lötsch J; Geisslinger G
    Trends Mol Med; 2005 Feb; 11(2):82-9. PubMed ID: 15694871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of opioid pharmacogenetics.
    Argoff CE
    Clin J Pain; 2010 Jan; 26 Suppl 10():S16-20. PubMed ID: 20026961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current evidence for a genetic modulation of the response to analgesics.
    Lötsch J; Geisslinger G
    Pain; 2006 Mar; 121(1-2):1-5. PubMed ID: 16472919
    [No Abstract]   [Full Text] [Related]  

  • 13. Opioids for chronic non-malignant pain.
    Conigliaro DA
    J Fla Med Assoc; 1996 Dec; 83(10):708-11. PubMed ID: 9019062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of genetic factors on opioid action.
    Kosarac B; Fox AA; Collard CD
    Curr Opin Anaesthesiol; 2009 Aug; 22(4):476-82. PubMed ID: 19502975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic modulation of the pharmacological treatment of pain.
    Lötsch J; Geisslinger G; Tegeder I
    Pharmacol Ther; 2009 Nov; 124(2):168-84. PubMed ID: 19615406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of opioids for chronic pain: a review of the evidence.
    Ballantyne JC; Shin NS
    Clin J Pain; 2008; 24(6):469-78. PubMed ID: 18574357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics in palliative care.
    Kleine-Brueggeney M; Musshoff F; Stuber F; Stamer UM
    Forensic Sci Int; 2010 Dec; 203(1-3):63-70. PubMed ID: 20709477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous opioid treatment for chronic noncancer pain: a time for moderation in prescribing.
    Colameco S; Coren JS; Ciervo CA
    Postgrad Med; 2009 Jul; 121(4):61-6. PubMed ID: 19641271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reviewing pharmacogenetics to advance precision medicine for opioids.
    Magarbeh L; Gorbovskaya I; Le Foll B; Jhirad R; Müller DJ
    Biomed Pharmacother; 2021 Oct; 142():112060. PubMed ID: 34523422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Postoperative pain management following orthognathic surgery in consideration of individual differences--is the antinociceptive effect of fentanyl related to the genotype involving nucleotide at OPRM1?].
    Fukuda K; Hayashida M; Ikeda K
    Masui; 2009 Sep; 58(9):1102-8. PubMed ID: 19764432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.